|  |  |
| --- | --- |
| Program Director/Principal Investigator (Last, First, Middle): |       |
| The name of the program director/principal investigator must be provided at the top of each printed page and each continuation page. |
| RESEARCH GRANT |
| TABLE OF CONTENTS |
|  | *Page Numbers* |
| Face Page  |  | 1 |  |
| Description, Project/Performance Sites, Senior/Key Personnel, Other Significant Contributors, and Human Embryonic Stem Cells  |  | 2 |  |
| Table of Contents  |  |       |  |
| Detailed Budget for Initial Budget Period  |  |       |  |
| Budget for Entire Proposed Period of Support  |  |       |  |
| Budgets Pertaining to Consortium/Contractual Arrangements  |  |       |  |
| Biographical Sketch – Program Director/Principal Investigator (*Not to exceed five pages each*)  |  |       |  |
| Other Biographical Sketches (*Not to exceed five pages each –* *See instructions*)  |  |       |  |
| Resources  |  |       |  |
| Checklist  |  |       |  |
|  |  |
| Research Plan  |  |       |  |
|  |  |
| 1. Introduction to Resubmission Application, if applicable, or Introduction to Revision Application, if applicable \*  |  |       |  |
| 2. Specific Aims \*  |  |       |  |
| 3. Research Strategy \*  |  |       |  |
| 4. Bibliography and References Cited/Progress Report Publication List  |  |       |  |
| 5. Vertebrate Animals  |  |       |  |
| 6. Select Agent Research  |  |       |  |
| 7. Multiple PD/PI Leadership Plan  |  |       |  |
| 8. Consortium/Contractual Arrangements  |  |       |  |
| 9. Letters of Support (e.g., Consultants)  |  |       |  |
| 10. Resource Sharing Plan(s)  |  |       |  |
| 11. Authentication of Key Biological and/or Chemical Resources  |  |       |  |
| 12. PHS Human Subjects and Clinical Trials Information  |  |       |  |
|  |  |
| Appendix *(Two identical CDs.)* |  [ ]  | Check if Appendix isIncluded |
| \* Follow the page limits for these sections indicated in the application instructions, unless the Funding Opportunity Announcement specifies otherwise. |

PHS 398 (Rev. 01/18 Approved Through 03/31/2020) OMB No. 0925-0001
 Page     Form Page 3